BRPI1007484A2 - composição farmacêutica para administração oral - Google Patents

composição farmacêutica para administração oral

Info

Publication number
BRPI1007484A2
BRPI1007484A2 BRPI1007484A BRPI1007484A BRPI1007484A2 BR PI1007484 A2 BRPI1007484 A2 BR PI1007484A2 BR PI1007484 A BRPI1007484 A BR PI1007484A BR PI1007484 A BRPI1007484 A BR PI1007484A BR PI1007484 A2 BRPI1007484 A2 BR PI1007484A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
oral administration
oral
administration
pharmaceutical
Prior art date
Application number
BRPI1007484A
Other languages
English (en)
Inventor
Akio Sugihara
Hiroyuki Yoshino
Kazuhiro Sako
Noriyuki Kinoshita
Shuuya Kawahama
Takehiko Yasuji
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42542065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1007484(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI1007484A2 publication Critical patent/BRPI1007484A2/pt
Publication of BRPI1007484B1 publication Critical patent/BRPI1007484B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1007484-8A 2009-02-04 2010-02-02 Composição farmacêutica formulada para administração oral compreendendo uma camada compreendendo uma porção de liberação modificada e uma camada compreendendo uma porção de liberação imediata BRPI1007484B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14985409P 2009-02-04 2009-02-04
US61/149.854 2009-02-04
PCT/JP2010/051393 WO2010090172A1 (ja) 2009-02-04 2010-02-02 経口投与用医薬組成物

Publications (2)

Publication Number Publication Date
BRPI1007484A2 true BRPI1007484A2 (pt) 2016-02-16
BRPI1007484B1 BRPI1007484B1 (pt) 2019-04-16

Family

ID=42542065

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007484-8A BRPI1007484B1 (pt) 2009-02-04 2010-02-02 Composição farmacêutica formulada para administração oral compreendendo uma camada compreendendo uma porção de liberação modificada e uma camada compreendendo uma porção de liberação imediata

Country Status (27)

Country Link
US (1) US9198904B2 (pt)
EP (1) EP2394648B1 (pt)
JP (1) JP5553026B2 (pt)
KR (1) KR20110126650A (pt)
CN (1) CN102307579B (pt)
AU (1) AU2010211725C1 (pt)
BR (1) BRPI1007484B1 (pt)
CA (1) CA2751039C (pt)
CY (1) CY1118057T1 (pt)
DK (1) DK2394648T3 (pt)
ES (1) ES2603747T3 (pt)
HR (1) HRP20161138T1 (pt)
HU (1) HUE029638T2 (pt)
IL (1) IL214420A (pt)
LT (1) LT2394648T (pt)
MX (1) MX342062B (pt)
MY (1) MY160652A (pt)
NZ (1) NZ594311A (pt)
PL (1) PL2394648T3 (pt)
PT (1) PT2394648T (pt)
RS (1) RS55151B1 (pt)
RU (1) RU2580652C2 (pt)
SG (1) SG173528A1 (pt)
SI (1) SI2394648T1 (pt)
UA (1) UA102885C2 (pt)
WO (1) WO2010090172A1 (pt)
ZA (1) ZA201105572B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5028893B2 (ja) 2006-07-18 2012-09-19 日産自動車株式会社 アンダーカバー
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
EP2500013B1 (en) * 2011-03-15 2019-10-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising solifenacin
CN102743757A (zh) * 2012-07-09 2012-10-24 张家华 治疗膀胱流出道梗阻所致膀胱活动过度的药物
HK1208801A1 (en) * 2012-08-31 2016-03-18 安斯泰来制药株式会社 Orally administered medical composition
KR101639692B1 (ko) * 2013-12-13 2016-07-14 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
JP6915258B2 (ja) * 2016-10-21 2021-08-04 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
WO2019076966A1 (en) * 2017-10-17 2019-04-25 Synthon B.V. TABLETS COMPRISING TAMSULOSIN AND SOLIFENACIN
WO2021220133A1 (en) 2020-04-27 2021-11-04 Zim Laboratories Limited Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin
UA130029C2 (uk) 2020-12-01 2025-10-15 Адамед Фарма С.А. Препарат, який вводиться перорально, що містить соліфенацин і тамсулозин

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558156A (en) * 1980-02-08 1985-12-10 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
EP0185117A1 (de) 1984-12-21 1986-06-25 IPEX Getränke-Herstellungs- und Vertriebsgesellschaft mbH Getränk
JPS62114952A (ja) 1985-11-13 1987-05-26 Yamanouchi Pharmaceut Co Ltd 置換フエネチルアミン誘導体の製造法
JP3140465B2 (ja) * 1992-09-18 2001-03-05 山之内製薬株式会社 ハイドロゲル徐放性製剤
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US6878386B1 (en) * 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
GB0129962D0 (en) * 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
JP5466346B2 (ja) * 2002-04-15 2014-04-09 レキット ベンキーザー エルエルシー グアイフェネシン組合せ剤の徐放
KR20050008795A (ko) * 2002-06-07 2005-01-21 야마노우치세이야쿠 가부시키가이샤 과활동 방광 치료제
JP4523265B2 (ja) * 2002-11-13 2010-08-11 旭化成ファーマ株式会社 排尿障害治療用口腔内崩壊製剤
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8128958B2 (en) 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
WO2006070735A1 (ja) * 2004-12-27 2006-07-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の安定な粒子状医薬組成物
CA2599158C (en) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
CN101754760A (zh) * 2007-07-20 2010-06-23 安斯泰来制药株式会社 用以改善伴随着前列腺肥大的下尿路症状的药物组合物
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
WO2010090172A1 (ja) 2010-08-12
JP5553026B2 (ja) 2014-07-16
HRP20161138T1 (hr) 2016-11-04
IL214420A (en) 2016-09-29
LT2394648T (lt) 2016-10-10
NZ594311A (en) 2013-05-31
EP2394648A1 (en) 2011-12-14
AU2010211725C1 (en) 2014-10-16
CN102307579A (zh) 2012-01-04
CN102307579B (zh) 2013-10-16
AU2010211725B2 (en) 2014-04-10
MY160652A (en) 2017-03-15
RU2580652C2 (ru) 2016-04-10
HUE029638T2 (en) 2017-03-28
KR20110126650A (ko) 2011-11-23
US20100233260A1 (en) 2010-09-16
SI2394648T1 (sl) 2017-02-28
IL214420A0 (en) 2011-09-27
CY1118057T1 (el) 2017-06-28
AU2010211725A1 (en) 2011-08-25
UA102885C2 (ru) 2013-08-27
CA2751039C (en) 2015-05-05
US9198904B2 (en) 2015-12-01
JPWO2010090172A1 (ja) 2012-08-09
MX2011008188A (es) 2011-09-29
EP2394648B1 (en) 2016-08-31
DK2394648T3 (en) 2016-09-26
PT2394648T (pt) 2016-10-03
SG173528A1 (en) 2011-09-29
ES2603747T3 (es) 2017-03-01
BRPI1007484B1 (pt) 2019-04-16
CA2751039A1 (en) 2010-08-12
ZA201105572B (en) 2012-09-26
EP2394648A4 (en) 2012-08-29
PL2394648T3 (pl) 2016-12-30
RU2011136636A (ru) 2013-03-10
RS55151B1 (sr) 2017-01-31
MX342062B (es) 2016-09-12

Similar Documents

Publication Publication Date Title
IL249747A0 (en) Antibacterial oral composition
BRPI1008598A2 (pt) composição farmacêutica para inalação
BRPI1007484A2 (pt) composição farmacêutica para administração oral
DK3097925T3 (da) Farmaceutisk sammensætning
HUE046748T2 (hu) Orális beadásra szánt kortikoszteroid készítmények
BRPI1004940A2 (pt) composição farmacêutica
EP2451274A4 (en) Pharmaceutical compositions
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
DK2632493T3 (da) Lægemiddelindgivelsessammensætninger
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
SMT201400069B (it) Formulazione farmaceutica
BRPI1015939A2 (pt) composição farmacêutica
EP2591773A4 (en) TEMPORARY RELEASED PHARMACEUTICAL COMPOSITION WITH DAPOXIN FOR ORAL ADMINISTRATION
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK2542224T3 (da) Oral farmaceutisk sammensætning indeholdende dabigatranetexilat
IT1394400B1 (it) Composizioni farmaceutiche
BRPI0922653A2 (pt) preparação farmacêutica
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
BR112012003149A2 (pt) composição farmacêutica
BR112012001340A2 (pt) composições farmacêuticas
BR112013014940A2 (pt) composições farmacêuticas de inibidores de fator xa seletivos para administração oral
BRPI1006076A2 (pt) composicoes farmaceuticas
BRPI0919194A2 (pt) preparação sólida para administração oral
DK2714042T3 (da) En analgetisk farmaceutisk sammensætning til oral administration

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2010, OBSERVADAS AS CONDICOES LEGAIS